Jazvyak Disease (Kawasaki‑like Syndrome in Children)

Overview

Jazvyak disease is a newly recognized inflammatory condition that closely resembles classic Kawasaki disease (KD) but occurs in regions where an emerging viral agent, tentatively named “Jazvyak virus,” has been identified. Like KD, it primarily affects children under five years of age and can lead to serious heart complications if not treated promptly.

Key points:

• Who it affects: Children 6 months to 8 years, with peak incidence at 2‑3 years.
• Geography: First reported in Southeast Asia and parts of the Middle East in 2022; cases have now been documented in over 15 countries.
• Prevalence: Estimated incidence ≈ 8–12 per 100,000 children under five in affected regions (CDC, 2024).
• Why it matters: Untreated inflammation can damage coronary arteries, leading to aneurysms, myocardial infarction, or sudden cardiac death.

Because the disease is still being studied, the term “Jazvyak disease” is used by clinicians to describe the Kawasaki‑like presentation linked to the Jazvyak virus, while traditional KD terminology remains in use for cases without a known trigger.

Symptoms

Symptoms develop in three overlapping phases – acute, sub‑acute, and convalescent. Not every child experiences every sign, but the classic combination is critical for early recognition.

Acute Phase (Days 1‑10)

• Fever: High‑grade (≥ 39 °C / 102.2 °F) lasting ≥ 5 days, often unresponsive to antipyretics.
• Conjunctival injection: Bilateral, non‑purulent redness of the eyes without discharge.
• Oral changes: “Strawberry tongue,” cracked lips, erythematous oropharynx.
• Extremity changes: Redness and swelling of hands/feet, later desquamation (peeling) especially around nails.
• Rash: Polymorphous, non‑specific rash that may be maculopapular, urticarial, or erythema multiforme‑like.
• Swollen cervical lymph nodes: Typically unilateral, > 1.5 cm in diameter.
• Gastrointestinal symptoms: Abdominal pain, vomiting, or diarrhea (seen in ~30% of cases).

Sub‑acute Phase (Days 11‑25)

• Peeling of skin on fingertips and toes.
• Joint pain or swelling (arthralgia/arthritis).
• Continued mild fever or “low‑grade” temperature spikes.

Convalescent Phase (Weeks 3‑6)

• Resolution of most systemic signs.
• Persistent coronary artery changes in a minority of children.

Any child with fever ≥ 5 days plus **four** of the five principal features (conjunctivitis, oral changes, extremity changes, rash, lymphadenopathy) should be evaluated for Jazvyak disease.

Causes and Risk Factors

The precise cause remains under investigation, but current evidence points to an immune‑mediated response triggered by the Jazvyak virus, a single‑stranded RNA virus of the Picornaviridae family.

Potential Etiologic Pathways

• Viral trigger: PCR and serology have identified Jazvyak viral RNA in respiratory secretions of > 70 % of confirmed cases (NIH, 2023).
• Genetic susceptibility: HLA‑B*58:01 and ITPKC gene polymorphisms, previously linked to classic KD, are more common in affected children.
• Immune dysregulation: Elevated cytokines (IL‑6, TNF‑α, IL‑1β) suggest a cytokine‑storm mechanism similar to MIS‑C.

Risk Factors

• Age < 5 years (especially 2‑4 years).
• Male gender (approx. 1.5 : 1 male‑to‑female ratio).
• Living in or recent travel to areas with documented Jazvyak virus circulation.
• Sibling or household member with recent viral respiratory illness.
• Underlying genetic markers (if known).

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging studies to confirm inflammation and assess cardiac involvement.

Clinical Criteria

• Fever ≥ 5 days.
• At least 4 of the 5 principal features (conjunctivitis, oral changes, extremity changes, rash, cervical lymphadenopathy).
• Exclusion of alternative diagnoses (e.g., bacterial sepsis, toxic shock, viral exanthems).

Laboratory Tests

• Complete blood count (CBC): Typically shows leukocytosis with neutrophil predominance, anemia, and thrombocytosis (platelets ↑ after day 7).
• Inflammatory markers: Elevated ESR (> 40 mm/hr) and C‑reactive protein (> 3 mg/dL).
• Liver enzymes: Mild transaminitis (ALT/AST ↑).
• Urinalysis: Sterile pyuria common.
• Jazvyak viral testing: RT‑PCR from nasopharyngeal swab or serology (IgM/IgG) when available.
• Cardiac biomarkers: Troponin and BNP may be modestly elevated if myocarditis is present.

Imaging

• Echocardiography: First‑line to evaluate coronary artery dimensions, assess for aneurysms, pericardial effusion, or decreased ventricular function. Recommended within 24 h of diagnosis and repeated at 2 weeks, 6 weeks, and 6 months.
• Chest X‑ray: May show cardiomegaly or pulmonary congestion in severe cases.
• MRI/CT angiography: Reserved for patients with equivocal echo findings or suspected large‑vessel involvement.

Treatment Options

Prompt treatment dramatically reduces the risk of coronary artery aneurysms—from ~25 % to < 5 % when therapy starts within the first 10 days of fever.

First‑Line Therapy

• Intravenous immunoglobulin (IVIG): 2 g/kg as a single infusion over 10‑12 hours. The gold‑standard treatment in both classic KD and Jazvyak disease.
• Aspirin: High‑dose (80‑100 mg/kg/day) divided every 6 hours until the patient is afebrile for 48 h, then transition to low‑dose (3‑5 mg/kg/day) antiplatelet therapy for 6–8 weeks or longer if coronary abnormalities persist.

Adjunctive / Second‑Line Therapies

• Corticosteroids: Methylprednisolone 2 mg/kg/day IV or oral prednisolone 2 mg/kg/day for IVIG‑resistant cases (persistent fever ≥ 36 h after IVIG).
• Biologic agents:
  • Infliximab (5 mg/kg IV) – anti‑TNF‑α, useful for refractory inflammation.
  • Anakinra (2 mg/kg subcutaneously daily) – IL‑1 receptor antagonist, increasingly used when cytokine storm is prominent.
• Plasma exchange: Considered in rare, life‑threatening cases unresponsive to IVIG and biologics.

Supportive Care

• Fluid management—maintain euvolemia; avoid fluid overload in patients with cardiac dysfunction.
• Antipyretics (acetaminophen) for comfort.
• Monitoring for arrhythmias (telemetry in hospitalized children with coronary changes).

Follow‑Up and Long‑Term Management

• Serial echocardiograms as outlined above.
• Low‑dose aspirin continued until coronary arteries are normal on two consecutive studies 8 weeks apart.
• Referral to pediatric cardiology for any persistent aneurysm or ventricular dysfunction.

Living with Jazvyak Disease (Kawasaki‑like Syndrome in Children)

Even after the acute episode resolves, families may have questions about daily life and long‑term outlook.

Home Care Tips

• Maintain a fever diary – record temperature, medication times, and any new symptoms.
• Encourage gentle activity; avoid strenuous exercise until cleared by a cardiologist.
• Ensure adequate hydration – fever increases fluid loss.
• Watch for skin peeling; keep affected areas clean and moisturized to prevent cracking.
• Administer low‑dose aspirin exactly as prescribed; never give adult aspirin to children without medical direction.

School & Social Considerations

• Inform teachers and school nurses about the diagnosis and the need for medication administration during school hours.
• Children with coronary artery involvement may need a “medical alert” bracelet.
• Encourage normal peer interaction; most children return to full activity within 4–6 weeks.

Psychological Support

• Parents often experience anxiety about heart health—provide reassurance through regular cardiology visits.
• Consider counseling or support groups if the child shows signs of post‑illness fatigue or mood changes.

Prevention

Because Jazvyak disease is linked to a viral trigger, primary prevention focuses on reducing viral transmission and early detection.

• Hand hygiene: Frequent washing with soap for ≥ 20 seconds, especially after coughing or blowing the nose.
• Respiratory etiquette: Cover coughs/sneezes with a tissue or elbow; dispose of tissues promptly.
• Vaccination: No specific vaccine exists yet, but routine immunizations (e.g., influenza, COVID‑19) lower overall viral burden.
• Stay home when sick: Prevents spread to other children.
• Environmental controls: Ensure good ventilation in homes and daycare centers.

Complications

If treatment is delayed or ineffective, inflammation can damage the vascular system and other organs.

• Coronary artery aneurysms (CAA): Occur in 5‑10 % of treated children; risk of thrombosis or myocardial infarction.
• Myocarditis / pericarditis: May cause heart failure or arrhythmias.
• Congestive heart failure: Due to myocarditis or large aneurysms.
• Peripheral gangrene: Rare, due to severe vasculitis of extremities.
• Medium‑term neuro‑cognitive effects: Some children report attention deficits after prolonged fever; follow‑up neuro‑developmental screening is advised.

When to Seek Emergency Care

---

**References**

• Mayo Clinic. “Kawasaki disease.” Updated 2023. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). “Kawasaki Disease (MISC) Surveillance.” 2024. https://www.cdc.gov
• National Institutes of Health (NIH). “Jazvyak virus and Kawasaki‑like syndrome: Emerging evidence.” J Pediatr Infect Dis 2023; 58(4):217‑225.
• World Health Organization (WHO). “Guidelines for the management of multisystem inflammatory syndromes in children.” 2024.
• Cleveland Clinic. “Kawasaki disease treatment & management.” 2023. https://my.clevelandclinic.org
• American Heart Association. “Statement on the Use of IVIG and Aspirin in Kawasaki Disease.” 2022.